Title: The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson's Disease: An

Updated Systematic Review

Running Title: COVID-19 and Parkinson's Disease

Authors: Vikash Jaiswal[1,2], Danah Alquraish[1], Zouina Sarfraz*[1,3], Shavy Nagpal[4], Prakriti Singh

Shrestha[4], Dattatreya Mukherjee**[5], Prathima Guntipalli[1], Azza Sarfraz[1,6], Diana F Sánchez

Velazco[7], Arushee Bhatnagar[1], Saloni Savani[1], Elmjedina Halilaj[1], Samir Ruxmohan[8], Wilson

Cueva[8]

Institutions:

1. Larkin Health System, South Miami, FL, USA

2. AMA School of Medicine, Makati, Philippines

3. Fatima Jinnah Medical University, Lahore, Pakistan

4. The Research Institute of St. Joe's Hamilton, ON, Canada

5. International School, Jinan University, P.R China

6. Aga Khan University, Karachi, Pakistan

7. Cayetano Heredia Peruvian University, Lima, Peru

8. Department of Neurology, Larkin Community Hospital, South Miami, FL, USA

*Corresponding Author: Zouina Sarfraz MBBS, Division of Research and Academic Affairs,

Larkin Health System, 7031 SW 62nd Avenue South Miami, FL 33143, USA. Email:

zouinasarfraz@gmail.com

**Medrxiv Corresponding: Dattatreya Mukherjee, MBBS Student, Jinan University, P.R China

Dattatreyamukherjee4u@outlook.com

#All Authors have Contributed Equally and Significantly

Conflicts of interest: All authors declare no conflict of interest.

Funding: None obtained.

Acknowledgments: We would like to acknowledge Samia Jahan, Madiha Zaidi, Wanessa

Matos, Sana Javed, Asma Mohammadi, and Sujan Poudel for their early contributions. All

authors are thankful to Jack Michel, and the Larkin Health System for boosting scholarly

research pursuits.

Abstract

Background: COVID-19 has affected global communities with multiple neurological
complications in addition to other critical medical issues. COVID-19 binds to the host's
angiotensin-converting enzyme2 (ACE2) receptors, which are expressed in the neurons and glial
cells, acting as an entry port to the central nervous system (CNS). ACE2 receptors are
abundantly expressed on dopamine neurons, which may worsen the prognosis of motor
symptoms in Parkinson's disease (PD). SARS-CoV-2 may lead to an indirect response via
immune-mediated cytokine storms and propagate through the CNS leading to damage. PD is also
been associated with certain post-viral infections apart from COVID-19, such as HSV,
Influenzavirus A, Measles virus, Cytomegalovirus, and Mumps.
41
42 **Objective:** In this systematic review, we aim to provide a thorough analysis of associations
43 between COVID-19 and neurological outcomes for patients with PD.
44
Methods: Using PRISMA statement 2020, a systematic review was conducted to isolate
confirmed COVID-19 patients and analyze the PD-associated neurological outcomes. A
systematic literature search was conducted using the following databases: PubMed, Science
Direct, Google Scholar, and Cochrane databases. The following keywords were used
"COVID19, SARS-CoV-2, Parkinson's disease, Pandemic, Mortality." A modified Delphi
process was employed to include the studies and ensure that the clinical outcome measures were
addressed.
52
Results: Of the 355 records located during the initial round of screening, 16 were included in the
final synthesis. Of PD patients who tested positive for SARS-CoV-2, worsening motor
symptoms and other viral-associated symptoms were reported. These symptoms included
bradykinesia, tremors, gait disturbances, delirium and dementia, and severe spasms of arms and
legs. Encephalopathy was presented in two of the included studies. Increased mortality rates
were identified for hospitalized patients due to COVID-19 and PD as compared to other patient
groups, albeit with limited generalizability due to high bias of included studies.
60
61 **Conclusion**: Patients with PD may experience substantial worsening of motor and non-motor
62 symptoms due to COVID 19. Given the novelty of neurological-viral associations, clinical
63 studies in the future ought to explore the disease severity and neurological outcomes in COVID-
64 19 positive patients with PD as compared to non-PD patients, in addition to understanding the
65 role of ACE2 in increased vulnerability to contracting the infection and as a treatment modality.
66
67 **Keywords**: COVID-19, Parkinson's disease, SARS-CoV-2, Neurological, ACE2
68

1. Introduction

At the onset of the coronavirus disease (2019) pandemic on 31 December 2019, many reports found that SARS-CoV-2 primarily caused pneumonia-like symptoms [1]. This virus emerged as a global threat and a public health emergency of imminent concern across countries worldwide, with exponential transmission capability. As of May 25, 2021, there have been 167 million confirmed cases of COVID-19, with reported deaths up to 3.47 million globally [2]. COVID-19 belongs to a novel member of the coronaviridae family named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) [3]. Coronaviruses are enveloped positive single-stranded RNA viruses, and the 3' terminal contains structural proteins. The Spike (S) protein allows the virus to fuse to host cell membranes in proximity to infected and uninfected cells [4]. A surge in the levels of cytokines (TNF￼α, IL￼6, IL￼8, and IL￼10) have been reported, leading to a suppression of T-cell response [5]. To date, a multitude of studies have assessed the role of angiotensin-converting enzyme2 (ACE2) receptors in increasing vulnerability of hosts, however, there is a dearth of analysis on the role of ACE inhibitors in treating Parkinson's disease (PD) patients. In this systematic review, we aim to provide an updated, thorough analysis of associations between COVID-19 and neurological outcomes for patients with PD.

Coronavirus disease (2019) has prompted many challenges in global healthcare systems due to its unpredictability and unique manifestations in 1) pulmonary, 2) neurological, 3) cardiovascular, 4) gastrointestinal, and 5) hematological systems. The scientific literature confirms the presence of SARS-CoV-2 in CSF, in addition to respiratory, fecal, and blood

samples. In about 36.4% of cases, neurological findings have been identified, ranging from

dizziness, headache, hyposmia, hypogeusia, dysphagia, muscle pain, seizures, and loss of

consciousness [6]. COVID-19 also influences socializing factors such as the surge in isolation-

induced neurological effects, limited social activities possibly leading to short or long-term

neuropsychiatric disorders.

We hypothesize that COVID-19 induced lockdowns, self-isolation, and the fears

associated with contracting disease accentuate neuro-psychiatric problems such as depression

and cognition. **Figure 1** illustrates motor and non-motor manifestations in addition to autonomic

manifestations that are pertinent in the assessment of the clinical outcomes of confirmed positive

PD patients. Given the dearth of data, we aim to provide a comprehensive and updated

systematic review to guide clinical care and practice in understanding the effects of COVID-19

on Parkinson's disease.

Parkinson's Disease Clinical Manifesations

Motor manifestations	Non-motor manifestations	Autonomic manifestations
1. Resting tremors	1. Cognitive adverse effects	1. Hypotensive episodes
2. Rigidity	2. Neuropsychiatric complications	2. Erectile dysfunction
3. Bradykinesia	3. Depression	3. Bladder complications
4. Postural instability	4. Apathy	

106
107 **Figure 1.** Clinical manifestations of Parkinson's disease.
108
109
110
111

2. Methodology

2.1. Search strategy

Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

2020 statement, a systematic literature search was performed from December 2019 through May

2021 [7]. The following set of keywords were used, employing the Boolean (and/or) logic:

"COVID19", "SARS-CoV-2", "Parkinson's disease," "Pandemic," "Mortality." We searched the

following databases, namely, PubMed, Cochrane, Science Direct, EMBASE, and Google

Scholar. A modified Delphi approach was utilized to include studies and ensure that the clinical

outcome measures are identified in a systematic and unanimous order in the included studies [8].

The PRISMA flowchart is illustrated in **Figure 2.**

Figure 2. PRISMA Flowchart.

2.2. Study selection

We included studies with confirmed COVID-19 disease who had a history of Parkinson's

disease. Only studies published in English and with open access availability were included. In

total, 355 records were located during the initial round of screening. During this round of

screening, all authors scanned the abstracts and titles independently, which led to the location of

155 records. In the second screening round, full-text records were screened, and 125 articles that

met the exclusion criteria were removed. During the third screening round, 84 records were

screened for eligibility. In total, 35 records were excluded as non-PD patient groups were

present, 16 records had incomplete data for sourcing, and 16 of the full-text records present with

post-COVID-19 PD development, which met the exclusion criteria. Finally, 16 articles were

included in the qualitative synthesis.

2.3. Eligibility criteria

The inclusion criteria for studies and the target population consisted of 1) COVID-19

patients with Parkinson's disease, 2) patients diagnosed with Parkinson's disease before COVID-

19 infection, 3) age group > 21 years old, 4) male and/or female, and 5) available articles in

English language only. Studies were excluded if they met one or more of the following criteria 1)

-COVID-19 negative PD patients, 2) studies on pregnant women, 3) the pediatric population, 4)

crossover study design, 5) commentaries/perspective pieces.

2.4. Data extraction and synthesis

The following data were extracted from eligible studies: serial number, author and year,

study design, sample size, gender, age, comorbidities, disease duration, PD outcomes, COVID-

19 associated symptoms. A shared spreadsheet was used to input data, which was extracted

independently by three authors for analysis and cumulative result interpretation (V.J., D.A.,

S.N.). The fourth reviewer (Z.S.) solved any discrepancies in data extraction and reach a

consensus in case of any disagreements.

Quality assessment was conducted by two authors (V.J. and Z.S.), who independently

assessed the (1) criteria of diagnosis of COVID-19 patients, (2) confirmed diagnosis of PD

before the COVID-19 pandemic, (3) PD sequelae in the included studies. A descriptive analysis

was conducted and presented for the included studies. Percentages and means were presented.

Frequent outcomes were reported if they have a frequency of at least 5% or more in the included

studies. The term PD complications were based on the motor, non-motor, and autonomic

complications mentioned in **Figure 1**.

2.5. Role of Funding

No funding was obtained for this study.

3. Results

Of the 355 records identified during the first round of screening, 16 studies comprising, 7

(43.8%) were case reports and case series, 4 (25%) case-control studies, 2 (12.5%) cross-

sectional, 2 (12.5%) cohort and 1 (6.25%) retrospective study were added (**Figure 3**) [9][10]

[11][12][13][14][15][16][17][18][19][20][21][22][23][24]. In total, a synthesis of 1290 PD patients with COVID-19 and the

characteristics of all included studies are presented in **Table 1**.

Figure 3. Types of studies included in the systematic review.

Male gender was predominant in 10 studies [9][10][11][12][13][14][15][16][17][18] and female gender was the

predominant one in 6 studies [17][19][20][21][22][23]. Of the available patient data, the cumulative mean of

age in years of included patients was 76.9 years. The average disease duration spanned 11 years

before the incidence of COVID-19 disease. Majority of the included patients presented with

comorbid conditions, comprising of hypertension [9,13,15,16,20,21,23,24], diabetes [10,12,16,18,19,20,21], obesity [9],

dyslipidemia [21], cardiovascular disease [9,10,14,15,19,20,21,24], immunocompromised [9,15,24], COPD [9,13,14,18],

asthma [18], chronic renal and liver diseases [18,19,24]. Of the PD patients that were tested and positive

infection with SARS-CoV-2, worsening of motor symptoms [9,10,11,14,15,16,18,19,21,23] including

bradykinesia, tremors, gait disturbances, delirium, and dementia [13,19] were noted; severe spasms

of the arms and legs [22] were found, with individual study percentages of motor symptoms

ranging from 19% to 100%, along with other COVD-19 symptoms. Encephalopathy was also

one of the major symptoms, which presented in 2 (12.5%) of the 16 studies [in 2023]. Mortality rates

for PD patients with COVID-19 who were hospitalized ranged from 5.7% to 100%

[9,10,11,12,13,14,15,16,18,19,20,21,22,24]. The mortality was notably 100% due to the inclusion of case reports.

4. **Discussion**

To our best understanding, this is the first systematic review to assess clinical outcomes

of Parkinson's disease (PD) in confirmed COVID-19 patients with a pre-pandemic PD diagnosis.

Wide varieties of neurological consequences have been reported in scientific literature among

COVID-19 positive patients [25,26,27,28,29,30,31,32,33]. Neurological symptoms comprised of the following

include those associated with core dysfunction (fatigue, headache, confusion, stroke [34], dizziness,

syncope [35], seizure, anorexia, and insomnia) [36,37,38], central-peripheral mixture (Guillain Barre

syndrome) [39], enteric, or peripheral nervous systems dysfunction (anosmia, ageusia, myoclonus

[40], neuropathic pain, and myalgia) [41]. The increase in hospital admission and mortality rates in

PD and other chronic neurological diseases during the COVID-19 pandemic is of imminent

concern as the long-term sequelae are currently undetermined. Most neurological diseases,

including PD, are dose-dependent on prescribed medications for symptomatic management. With

the compounded neuropsychiatric symptoms due to social isolation and outpatient clinics,

temporarily being suspended and irregular visits, these are causative in worsening PD symptoms

among COVID-19 patients [42].

In this systematic review, we included studies with COVID-19 positive patients with a

prior history of Parkinson's disease. The most common manifestations due to COVID-19 in PD

patients were found to be motor dysfunction. The majority of the studies showed a common

motor deficit domain in the range of moderate to severe. Some of the patients presented with

delirium, dementia, and encephalopathy among other COVID-19 complications. We posit that

this may be related to the ACE2 mechanism in the nervous system. It is postulated that SARS-

CoV-2 enters the cell, increases the activity of T cells, causing vasodilation, thrombosis, and

hypoxemia, which may then lead to stroke and seizures. One theory supports the effect of the

virus by stating that SARS-COV-2 attacks ACE 2 receptors in a multi-organ manner, targeting

the brain. A study found that ACE2 receptors act locks on cells and the SARS-CoV-2 spike

proteins act rapidly multiply on entering the cells. These ACE2 receptors control tissues in the

eye, reproductive system, renal-excretory, digestive, and respiratory system, and 21 different

regions of the brain, which require further deliberation in PD patients [43].

We found that the average age of all participants was 76.9 years with a male

predominance, in addition to a prior disease duration of 11 years. The majority of the patients

reported the presence of other comorbidities, of which the following were the most common:

hypertension, diabetes, obesity, dyslipidemia, cardiovascular disease, immunocompromised,

COPD, asthma, chronic renal and chronic liver diseases. Documented COVID-19 neurological

complications include stroke, especially in younger patients, reflecting the hypercoagulable state,

leukoencephalopathy, and hemorrhagic leukoencephalopathy. Although direct encephalitis was

documented, it is rare but does occur. Further, cranial neuropathies are also infrequent but

include the loss of sense of smell (cranial nerve 1) and Bell's palsy (cranial nerve 7) [44]. There

have been neurocognitive signs, particularly in older age groups that warrant further associations

to PD symptoms, clinical care, and management in the short and long term.

5. Limitations

We had certain limitations. The first included the presence of confounder factors. These

related to the finding that multiple studies of patients with elderly PD patients had other

comorbidities, possibly leading to an overrepresentation of findings. Secondly, the duration of

PD and the severity of the pre-pandemic symptoms possibly influenced the synthesis of clinical

outcomes due to COVID-19 infection. Thirdly, pertinent information, including prior and current

medications and compliance to treatment was lacking, leading to a lack of generalized

recommendations for PD and COVID-19 clinical care. While the inclusion of case reports may

deviate from generalizations in our findings, we believe they are pertinent for long-term PD

patients with acquired COVID-19 infection.

6. Conclusion

COVID-19 has a peaked mortality rate in older age groups, compounded with comorbid

conditions. The CNS is increasingly susceptible to SARS-CoV-2, deteriorating neurological

findings, particularly in patients with PD. We find that motor dysfunction, delirium, dementia,

severe spasms of arms and legs, and encephalopathy are pertinent clinical findings in PD patients

and ought to be addressed in current care and practice. The susceptible groups of COVID-19

positive patients with a history of PD are elderly males with 10 years or longer duration of illness

and other comorbid conditions. It is still unclear how SARS-CoV2 affects the long-term health

of the nervous system in PD patients. It is recommended that healthcare practitioners address

diminished neurological outcomes, changes in hospital stay, and raised mortality in PD patients.

7. References

1.   Wu, Y. C., Chen, C. S. & Chan, Y. J. The outbreak of COVID-19: An overview. *Journal*

of the Chinese Medical Association (2020) doi:10.1097/JCMA.0000000000000270.

2.   WHO. WHO Coronavirus Disease Dashboard. *WHO.int* (2021).

3.   Favalli, E. G. *et al.* COVID-19 infection and rheumatoid arthritis: Faraway, so close!

Autoimmunity Reviews (2020) doi:10.1016/j.autrev.2020.102523.

4.   Umakanthan, S. *et al.* Origin, transmission, diagnosis and management of coronavirus

disease 2019 (COVID-19). *Postgraduate Medical Journal* (2020)

doi:10.1136/postgradmedj-2020-138234.

5.   Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C. & Melguizo-

Rodríguez, L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.

Cytokine and Growth Factor Reviews (2020) doi:10.1016/j.cytogfr.2020.06.001.

6.   Bhidayasiri, R., Virameteekul, S., Kim, J. M., Pal, P. K. & Chung, S. J. COVID-19: An

early review of its global impact and considerations for parkinson's disease patient care.

Journal of Movement Disorders (2020) doi:10.14802/jmd.20042.

7.   Page, M. J. *et al.* The PRISMA 2020 statement: An updated guideline for reporting

systematic reviews. *The BMJ* (2021) doi:10.1136/bmj.n71.

8.   Sarfraz, A. *et al.* Randomized controlled trials of remdesivir in hospitalized coronavirus

disease 2019 patients: A meta-analysis. *Turkish J. Emerg. Med.* (2021) doi:10.4103/2452-

2473.309139.

9.   Cilia, R. *et al.* Effects of COVID-19 on Parkinson's Disease Clinical Features: A

Community-Based Case-Control Study. *Mov. Disord.* (2020) doi:10.1002/mds.28170.

10.   Del Prete, E. *et al.* Prevalence and impact of COVID-19 in Parkinson's disease: evidence

from a multi-center survey in Tuscany region. *J. Neurol.* (2020) doi:10.1007/s00415-020-

10002-6.

11.   Zhai, H. *et al.* Characteristic of Parkinson's disease with severe COVID-19: a study of 10

cases from Wuhan. *J. Neural Transm.* (2021) doi:10.1007/s00702-020-02283-y.

12.   Lo Monaco, M. R., Colacicco, G., Marotta, J. & Bentivoglio, A. R. An educational case

series of Parkinson's disease during the COVID-19 pandemic. *Revue Neurologique* (2021)

doi:10.1016/j.neurol.2020.07.007.

13.   Fasano, A. *et al.* Predictors of COVID-19 outcome in Parkinson's disease. *Park. Relat.*

Disord. (2020) doi:10.1016/j.parkreldis.2020.08.012.

14.   Filatov, A., Sharma, P., Hindi, F. & Espinosa, P. S. Neurological Complications of

Coronavirus Disease (COVID-19): Encephalopathy. *Cureus* (2020)

doi:10.7759/cureus.7352.

15.   Brown, E. G. *et al.* The Effect of the COVID-19 Pandemic on People with Parkinson's

Disease. *J. Parkinsons. Dis.* (2020) doi:10.3233/JPD-202249.

16.   Kobylecki, C., Jones, T., Lim, C. K., Miller, C. & Thomson, A. M. Phenomenology and

Outcomes of In-Patients With Parkinson's Disease During the Coronavirus Disease 2019

Pandemic. *Movement Disorders* (2020) doi:10.1002/mds.28205.

17.   Lo Monaco, M. R., Bentivoglio, A. R., Fusco, D., Calabresi, P. & Piano, C. Subacute

onset dystonia in a woman affected by Parkinson's disease following SARS-COV-2

infection. *Clin. Park. Relat. Disord.* (2021) doi:10.1016/j.prdoa.2020.100082.

18.   Antonini, A., Leta, V., Teo, J. & Chaudhuri, K. R. Outcome of Parkinson's Disease

291   Patients Affected by COVID-19. *Movement Disorders* (2020) doi:10.1002/mds.28104.

292   19.   Vignatelli, L. *et al.* Risk of Hospitalization and Death for COVID-19 in People with

293   Parkinson's Disease or Parkinsonism. *Mov. Disord.* (2021) doi:10.1002/mds.28408.

294   20.   Artusi, C. A. *et al.* COVID-19 in Parkinson's disease: Report on prevalence and outcome.

295   *Parkinsonism and Related Disorders* (2020) doi:10.1016/j.parkreldis.2020.09.008.

296   21.   Santos-García, D. *et al.* Impact of Coronavirus Disease 2019 Pandemic on Parkinson's

297   Disease: A Cross-Sectional Survey of 568 Spanish Patients. *Mov. Disord.* (2020)

298   doi:10.1002/mds.28261.

299   22.   Sainz-Amo, R. *et al.* COVID-19 in Parkinson's disease: what holds the key? *J. Neurol.*

300   (2020) doi:10.1007/s00415-020-10272-0.

301   23.   Li, J. *et al.* Management of a Parkinson's disease patient with severe COVID-19

302   pneumonia. *Ther. Adv. Chronic Dis.* (2020) doi:10.1177/2040622320949423.

303   24.   de Marcaida, J. A. *et al.* Clinical characteristics of coronavirus disease 2019 (COVID-19)

304   among patients at a movement disorders center. *Geriatr.* (2020)

305   doi:10.3390/GERIATRICS5030054.

306   25.   Prasad, S. *et al.* Parkinson's Disease and COVID-19: Perceptions and Implications in

307   Patients and Caregivers. *Movement Disorders* (2020) doi:10.1002/mds.28088.

308   26.   Helmich, R. C. & Bloem, B. R. The Impact of the COVID-19 Pandemic on Parkinson's

309   Disease: Hidden Sorrows and Emerging Opportunities. *Journal of Parkinson's Disease*

310   (2020) doi:10.3233/JPD-202038.

311   27.   Stoessl, A. J., Bhatia, K. P. & Merello, M. Movement Disorders in the World of COVID-

312   19. *Movement Disorders* (2020) doi:10.1002/mds.28069.

28. Papa, S. M. *et al.* Impact of the COVID-19 Pandemic on Parkinson's Disease and

Movement Disorders. *Movement Disorders Clinical Practice* (2020)

doi:10.1002/mdc3.12953.

29. Mao, L. *et al.* Neurologic Manifestations of Hospitalized Patients with Coronavirus

Disease 2019 in Wuhan, China. *JAMA Neurol.* (2020) doi:10.1001/jamaneurol.2020.1127.

30. Esposito, G. *et al.* Can the enteric nervous system be an alternative entrance door in

SARS-CoV2 neuroinvasion? *Brain, Behavior, and Immunity* (2020)

doi:10.1016/j.bbi.2020.04.060.

31. Li, Y. C., Bai, W. Z. & Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may

play a role in the respiratory failure of COVID-19 patients. *Journal of Medical Virology*

(2020) doi:10.1002/jmv.25728.

32. Moriguchi, T. *et al.* A first case of meningitis/encephalitis associated with SARS-

Coronavirus-2. *Int. J. Infect. Dis.* (2020) doi:10.1016/j.ijid.2020.03.062.

33. Poyiadji, N. *et al.* COVID-19-associated acute hemorrhagic necrotizing encephalopathy:

Imaging features. *Radiology* (2020) doi:10.1148/radiol.2020201187.

34. Beyrouti, R. *et al.* Characteristics of ischaemic stroke associated with COVID-19. *Journal*

of Neurology, Neurosurgery and Psychiatry (2020) doi:10.1136/jnnp-2020-323586.

35. Ebrille, E. *et al.* Syncope as the presenting symptom of COVID-19 infection. *Hear. Case*

Reports (2020) doi:10.1016/j.hrcr.2020.04.015.

36. Lechien, J. R. *et al.* Clinical and epidemiological characteristics of 1420 European patients

with mild-to-moderate coronavirus disease 2019. *J. Intern. Med.* (2020)

doi:10.1111/joim.13089.

37. Zanin, L. *et al.* SARS-CoV-2 can induce brain and spine demyelinating lesions. *Acta*

Neurochir. (Wien). (2020) doi:10.1007/s00701-020-04374-x.

38.   Rogers, J. P. *et al.* Psychiatric and neuropsychiatric presentations associated with severe

coronavirus infections: a systematic review and meta-analysis with comparison to the

COVID-19 pandemic. *The Lancet Psychiatry* (2020) doi:10.1016/S2215-0366(20)30203-

0.

39.   Toscano, G. *et al.* Guillain–Barré Syndrome Associated with SARS-CoV-2. *N. Engl. J.*

Med. (2020) doi:10.1056/nejmc2009191.

40.   Rábano-Suárez, P. *et al.* Generalized myoclonus in COVID-19. *Neurology* (2020)

doi:10.1212/WNL.0000000000009829.

41.   Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel

Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* (2020)

doi:10.1001/jama.2020.1585.

42.   Guo, D. *et al.* Influence of the COVID-19 Pandemic on Quality of Life of Patients with

Parkinson's Disease. *Parkinsons. Dis.* (2020) doi:10.1155/2020/1216568.

43.   Lukiw, W. J., Pogue, A. & Hill, J. M. SARS-CoV-2 Infectivity and Neurological Targets

in the Brain. *Cell. Mol. Neurobiol.* (2020) doi:10.1007/s10571-020-00947-7.

44.   Costello, F. & Dalakas, M. C. Cranial neuropathies and COVID-19: Neurotropism and

autoimmunity. *Neurology* (2020) doi:10.1212/WNL.0000000000009921.

No	Author	Study Design	Sample (N) PD	Males, %	Age, Mean	Comorbidities %	Disease duration, mean	Outcomes	PD related symptoms With COVID %
1	Cilia R et al, 2020	Case-control	12 cases 36 control	41.7 % cases 41.7% controls	65.5 years cases 66.3 years control	8.3% COPD 33.3 HTN 8.3% obesity 8.3% cardiopathy 16.7 % cancer 8.3% immuno-compromised	6.3 years cases 6.1 years control	50% affected by COVID-19 (cases group); 0% affected by COVID-19 in control group, 8.3% hospitalized	Worsening of motor symptoms
2	Del Prete, Eleonora, et al.2020	Case-control	7 cases 14 control	57.2% cases 57.2 % control	75.7 years cases versus 75 years control	Cases: 71.5% HTN 42.8% diabetes 28.5% cardiomyopathy 14.2% malignancies	9.3 years cases 8.9 years control	13 % mortality 14% case fatality	30% worsening

3	Hainque E et al, 2020	Case report	2	50 %	77.5	HTN	22y	100 %	100% worsening
4	Lo Monaco MR et al, 2020	Case series	5	66.6 %	74.2	20% Chronic Renal failure 20% Diabetes hypertension	NA	20% case fatality	60% Worsening
5	Fasano, Alfonso, et al. 2020	Case-control survey	105	52.4%	70.5	Obesity 18.1 % HTN 41.9% COPD 5.6% Diabetes 7.6% Cancer .9 %	9.9 y	17.1% hospitalized 5.7 % mortality	
6	Filatov, Asia, et al.202I	Case report	1		74	atrial fibrillation cardioembolic stroke COPD	NA	Icu hospitalization Poor prognosis	Encephalopat hy
7	Brown EG, et al,	Cross sectiona	51	47 %	65	Immunocompromis ed 22%	0–3y 21	9.8% Hospitalized	55 % worsening

	2020	1				Heart Disease 20% HTN 25% Lung disease 14%	3–6y 12 6–9y 9 >9y 9	3.9% ICU 2% Ventilator	18 % new PD symptoms
8	Kobylecki C et al 2020	Cohort, observational	58	62.5 %	78.3	Diabetes 8% HTN 38%	9.5	22.4% Mortality rate	69% Delirium 54% Dementia
9	Lo Monaco MR et al, 2021	Case report	1	0%	58	NA	8 y	NA	severe spasms of arms and legs.
10	Antonini et al 2020	case series	10	60 %	78.3	Diabetes Orthostatic hypotension CHF, COPD Asthma IHD, CKD, dementia, osteoporosis	12.7 y	40% mortality rate	Worsening of mobility with fall Worsening of motor symptoms Worsening of anxiety

					anxiety disorder			
11	Vignatelli et al, 2020	cohort	696 PD 184 parkinson ism control 8590	58.8 & PD 57.1 parkinson ism 58.2 control	75 PD 80.5 PS Control 76.0	PD and PS 22.6 % cardiomyopathies 14.6 % Cerebrovascular disease 8.5 % Chronic pulmonary disease .3 % Liver disease 5 %Renal disease 10% DM 8.5% malignancies	NA	Hospitalization 0.6% PD 3.3% PS 0.7% control Mortality rate 35.1% in all group	PD: 72.8%Tremo r 80,4% Bradykinesia 81.6% Clinical features at onset unilateral PS: 52.5%Tremo r 89.2 % Bradykinesia 52.5% Clinical

								features at onset unilateral
12	Artusi CA,et al, 2020	multiple case reports	8	62.5%	74	HTN diabetes, depression lung neoplasm Atrial fibrillation	12.2 y	75% mortality rate	50% worsening of PD symptoms
13	Diego Santos-García et al,	cross-sectional	15	47.1%	76.3	26.7% HTN 20% DM 64.3%Dyslipidemia 13.3%Cardiomyopathy 6.7% Valvular cardiomyopathy 20% Cardiac Arrhythmia 6.7%Cardiac Insufficiency 14.3%Pulmonary	NA	33.3% Hospitalized	65.7% worsening of symptoms 47.7% bradykinesia 41.4% sleep problems 40.7% rigidity 34.5% gait disturbances 31.3%

					disease 6.7% smoking			anxiety 28.5% pain 28.3% fatigue 27.6% Depression 20.8% tremor
14	R Sainz Amo et al. 2020	Case Control	Case: 33 Control:1 72	5 59	Case:75.9 Control: 73.9	36% Dementia	Case: 8.9 Control8 .5	54% hospitalization 21% mortality rate	NA
15	Jing li et al. 2020	Case report	1	Female	85	HTN Stroke	6 y		worsening motor symptoms. Encephalopat hy
16	De Marcaida et al 2020	Retrosp ective	36 22 PD	64 %	74.5	HTN cardiovascular	16.2 y	67% hospitalization 36% mortality	75% Alteration

						disease			mental status
						renal disease, diabetes			19 % worsening of their Movement abnormality
						chronic lung disease			
						immunosuppressio n			31% worsening mobility

361　　**Table 1.** Characteristics of included studies.

363